Comprehensive Drug Panel including Synthetic Cannabinoids and Designer Drugs, Solid Test (7473SL)
||Comprehensive Drug Panel including Synthetic Cannabinoids and Designer Drugs, Solid
||Identification of Synthetic Cannabinoids, Controlled Substances, Pharmaceutical Preparations, Bath Salts, and Designer Drugs.
**Contact lab for specific analytes covered in this panel**
||Bath Salts, Controlled Substances, Designer Drugs, Prescription and Over the Counter Preparations and the Synthetic Cannabinoids to include:; 5-MeO-DALT; delta-9-tetrahydrocannabinol (THC); K2; Spice; AM-694; AM-1220, AM-1241; AM-1248, AM-2201; AM-2233; CB-13, CB-25; CB-52; CP 47, 497 (C7); CP 47,497 (C8) (Cannabicyclohexanol); CP 55,940; HU-210; HU-211; HU-308; HU-331; JP-104, JWH-007; JWH-015; JWH-018 1-Methyl hexyl homolog; JWH-018 6-Methoxyindole analog; JWH-018 Chloropentyl Analog, JWH-019; JWH-020; JWH-022; JWH-072, JWH-073 Methyl butyl homolog; JWH-081; JWH-098; JWH-122; JWH-133; JWH-147; JWH-175; JWH-200; JWH-201; JWH-203; JWH-210; JWH-250; JWH-251; JWH-302; JWH-307, JWH-398; JTE-907; RCS-4; RCS-8; RCS-8 4-Methoxy Isomer; UR-144, URB-447, URB-597; URB-602; URB-754; URB-937, WIN 48,098 (Pravadoline); WIN 55,212-2; WIN 55,212-3, XLR-11
||Criminal/Civil Investigation; Identification of Synthetic Cannabinoids, Controlled Substances, Pharmaceutical Preparations, Bath Salts, and Designer Drugs; New York State test approval status is Undetermined.
||Drug Analysis, Drug Chemistry
||Thin Layer Chromatography (TLC)
Gas Chromatography/Mass Spectrometry (GC/MS)
High Performance Liquid Chromatography/Tandem QuadrupoleMass Spectrometry (LC/MS/MS)
GC/MS Derivatization (BSTFA)
||Call Laboratory for Specimen Requirements.
||Consultation with Laboratory is required prior to sample submission.
|Day(s) Test Set-up / TAT
||Turnaround time: 3 weeks
|Test Summary Sheet
*Rejection criteria pertain to clinical specimen submissions only.
**Stated minimum volume allows for a single analysis. Repeat analysis will not be performed.